Thyrocare Technologies Management

Management criteria checks 0/4

Thyrocare Technologies' CEO is Rahul Guha, appointed in May 2022, has a tenure of 2.08 years. directly owns 0.099% of the company’s shares, worth ₹34.17M. The average tenure of the management team and the board of directors is 1.5 years and 2.8 years respectively.

Key information

Rahul Guha

Chief executive officer

₹31.8m

Total compensation

CEO salary percentage	n/a
CEO tenure	2.1yrs
CEO ownership	0.1%
Management average tenure	1.5yrs
Board average tenure	2.8yrs

Recent management updates

Recent updates

CEO

Rahul Guha (46 yo)

2.1yrs

Tenure

₹31,801,079

Compensation

Mr. Rahul Franklin Guha is Managing Director, Chief Executive Officer and Director of Thyrocare Technologies Limited from May 04, 2022 and also serves as its Chairman since April 07, 2023. He joined the Th...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Rahul Guha	MD, CEO & Chairman	2.1yrs	₹31.80m	0.099% ₹ 34.2m
K. KallathiKumar	Chief Operating Officer	no data	₹9.89m	0.0030% ₹ 1.0m
Ramjee Dorai	Company Secretary & Compliance Officer	9.8yrs	₹3.09m	0.040% ₹ 13.8m
Aditya Shinde	Vice President	no data	₹5.33m	0.0020% ₹ 689.3k
Alok Jagnani	Chief Financial Officer	less than a year	no data	0% ₹ 0
Pratik Hire	Head of Strategy & Investor Relations	no data	no data	no data
Nitin Chugh	Chief Commercial Officer	less than a year	no data	no data

1.5yrs

Average Tenure

46yo

Average Age

Experienced Management: 539871's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Rahul Guha	MD, CEO & Chairman	2.1yrs	₹31.80m	0.099% ₹ 34.2m
Gopal Krishna Hegde	Independent Non-Executive Director	9.8yrs	₹160.00k	no data
Neetin Desai	Independent Non-Executive Director	9.8yrs	₹50.00k	no data
Indumati Gopinathan	Non-Executive Independent Director	6.8yrs	₹70.00k	no data
Dharmil Sheth	Non-Executive & Non-Independent Director	2.8yrs	no data	no data
Hardik Dedhia	Non Executive Director	2.8yrs	no data	no data
Dhaval Shah	Non Executive Director	2.7yrs	no data	no data
Prapti Gilada	Independent Director	less than a year	no data	no data
Harshil Vora	Non-Executive Independent Director	less than a year	no data	no data

2.8yrs

Average Tenure

36yo

Average Age

Experienced Board: 539871's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.

Thyrocare Technologies Management

Management criteria checks 0/4

Key information

Recent management updates

High number of new directors

MD, CEO & Chairman recently bought ₹4.3m worth of stock

Thyrocare Technologies Limited Appoints Alok Kumar Jagnani as Chief Financial Officer

High number of new directors

Thyrocare Technologies Limited Accepts Resignation of Sachin Salvi as Chief Financial Officer

Thyrocare Technologies Limited Announces Resignation of Vishwas Kulkarni as an Independent Director

Recent updates

Now 23% overvalued after recent price rise

Thyrocare Technologies Limited Proposes Final Dividend for the Financial Year 2023-24

Thyrocare Technologies Limited to Report Q4, 2024 Results on May 14, 2024

Thyrocare Technologies Limited (BSE:539871) completed the acquisition of Think Health Diagnostic Private Limited.

High number of new directors

Third quarter 2024 earnings released: EPS: ₹2.78 (vs ₹1.89 in 3Q 2023)

Thyrocare Technologies Limited to Report Q3, 2024 Results on Feb 01, 2024

Price target increased by 7.3% to ₹695

Second quarter 2024 earnings released: EPS: ₹3.84 (vs ₹3.80 in 2Q 2023)

Thyrocare Technologies Limited to Report Q2, 2024 Results on Oct 31, 2023

MD, CEO & Chairman recently bought ₹4.3m worth of stock

Thyrocare Technologies Limited Appoints Alok Kumar Jagnani as Chief Financial Officer

Price target decreased by 18% to ₹643

High number of new directors

Thyrocare Technologies Limited to Report Q1, 2024 Results on Aug 01, 2023

Full year 2023 earnings: EPS and revenues miss analyst expectations

Thyrocare Technologies Limited Accepts Resignation of Sachin Salvi as Chief Financial Officer

Consensus EPS estimates fall by 27%

Full year 2023 earnings: EPS and revenues miss analyst expectations

Thyrocare Technologies Limited to Report Q4, 2023 Results on May 23, 2023

Thyrocare Technologies Limited Announces Resignation of Vishwas Kulkarni as an Independent Director

Upcoming dividend of ₹18.00 per share at 3.1% yield

MD, CEO & Director recently bought ₹10m worth of stock

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Thyrocare Technologies Limited to Report Q3, 2023 Results on Feb 03, 2023

Consensus EPS estimates fall by 19%

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Thyrocare Technologies Limited (BSE:539871) agreed to acquire 51% stake in Pulse Hitech Health Services (Ghatkopar) LLP for INR 25.5 million.

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Thyrocare Technologies Limited to Report Q2, 2023 Results on Nov 11, 2022

MD, CEO & Director recently bought ₹16m worth of stock

Consensus EPS estimates fall by 12%

Thyrocare Technologies Limited Announces Payment of Interim Dividend for the Financial Year 2021-2022

Full year 2022 earnings: EPS and revenues miss analyst expectations

Thyrocare Technologies Limited, Annual General Meeting, Aug 03, 2022

Price target decreased to ₹1,073

Consensus forecasts updated

Thyrocare Technologies Limited Joins Rahul Guha as Managing Director

Thyrocare Technologies Limited Declares Interim Dividend for the Financial Year 2021-22

Full year 2022 earnings: EPS and revenues miss analyst expectations

Thyrocare Technologies Limited to Report Q4, 2022 Results on Apr 29, 2022

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Thyrocare Technologies Limited Announces Appointment of Rahul Guha as Managing Director

Thyrocare Technologies Limited Appoints Sachin Salvi as Chief Financial Officer

First quarter 2022 earnings released: EPS ₹10.51 (vs ₹0.04 in 1Q 2021)

Consensus forecasts updated

First quarter 2022 earnings released: EPS ₹10.51 (vs ₹0.04 in 1Q 2021)

Price target increased to ₹1,233

Docon Technologies Private Limited entered into a share purchase agreement to acquire 66.11% stake in Thyrocare Technologies Limited (BSE:539871) from a group of shareholders for INR 45.5 billion.

Pharmeasy Looks to Acquire a Stake in Thyrocare

Investor sentiment improved over the past week

Upcoming dividend of ₹15.00 per share

Full year 2021 earnings released: EPS ₹21.41 (vs ₹16.74 in FY 2020)

Full year 2021 earnings released: EPS ₹21.41 (vs ₹16.74 in FY 2020)

Investor sentiment improved over the past week

New 90-day low: ₹868

Analysts lower EPS estimates to ₹20.97

Third quarter 2021 earnings released: EPS ₹6.13 (vs ₹5.21 in 3Q 2020)

Revenue and earnings miss expectations

New 90-day low: ₹903

Thyrocare Technologies Limited to Report Q3, 2021 Results on Jan 30, 2021

Chairman & MD recently bought ₹6.3m worth of stock

Upcoming Dividend of ₹10.00 Per Share

Analysts increase revenue estimates to ₹5.34b

First half earnings released

Second-quarter earnings released: Revenue misses expectations

New 90-day high: ₹1,136

Price target raised to ₹775

Chairman recently bought ₹20m worth of stock